Navigation Links
BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
Date:5/21/2013

JUPITER, Fla., May 21, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb , its President and CEO, will be presenting at the Marcum MicroCap Conference.  

The conference will be held on Thursday, May 30, 2013 at the Grand Hyatt Hotel, located at 109 E 42nd Street in New York City.  Mr. Weinreb's presentation will take place at 2:30 ET in room six.  To listen to the webcast, please visit http://wsw.com/webcast/marcum/brtx.

The event will host nearly 100 publicly traded companies with capitalizations under $500 million. It is anticipated that the conference will be attended by more than 1,000 persons, including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace. The conference will also feature panels on subjects highly relevant to small-cap corporate finance.

For full event details and registration information, please go to:
www.marcumllp.com/microcap

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

  • brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures.  This research is still in the non-clinical, investigational stage.
  • ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
  • brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin.  Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contact:
Jeff Ramson

ProActive Capital
(646) 863-6341

jramson@proactivecapital.com


'/>"/>
SOURCE BioRestorative Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioRestorative Therapies Appoints ProActive Capital Group as Capital Markets & Digital Media Advisor
2. BioRestorative Therapies Announces One-for-Fifty Reverse Stock Split
3. BioRestorative Therapies to Present at Marcum MicroCap Conference
4. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. STAAR Surgical To Present At Upcoming Investor Conferences
7. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
8. Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
9. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
(Date:1/19/2017)... 18, 2017  ViewRay, Inc. (Nasdaq: ... only clinical MRI-guided radiation therapy system, announced today that ... $26.1 million through a private placement of its ... the financing and was joined by certain of ... Kearny Venture Partners, and an additional new institutional ...
(Date:1/19/2017)... Jan. 18, 2017 The Academy of ... Drug Administration (FDA) for its release today of ... health decision makers can proactively share clinical and ... well as emerging therapies awaiting FDA approval. ... recommendations that AMCP developed during two multi-stakeholder meetings ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy ... enhancement of their 503A compounding pharmacy located in Ocala, Florida. , Meeting ... and patients throughout the United States for high-quality human anti-aging and wellness ...
(Date:1/19/2017)... , ... January 19, 2017 , ... WhoHaha , ... up with the American Heart Association (AHA) to produce a three-part video series that ... will debut as part of the launch of AHA’s Healthy For Good™ movement, which ...
(Date:1/19/2017)... Somerset, N.J. (PRWEB) , ... January 19, 2017 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... Medicines with Lipids,” with Gattefossé, the leader in innovative excipients and drug delivery ...
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, ... fillers that resulted in severe facial disfiguration. After four frightening years of isolation ... at UCLA Medical Center, who removed the substances in a partial facial transplant ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy (UMA) ... are passionate about making a difference in the lives of the next generation ... a nonprofit healthcare educational institution, has more than 30,000 alumni and employs more ...
Breaking Medicine News(10 mins):